In BC, CD8+ T cells are associated with enhanced therapeutic responses[46] and survival[47], whereas CD4+ regulatory T cells exert more complex effects, being linked to both favorable and unfavorable outcomes[48-51]. The gene discussed is CD8A; the disease is breast cancer.